

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: A61K 37/02, 37/36, C07K 7/10	A1	(11) International Publication Number: WO 93/06845 (43) International Publication Date: 15 April 1993 (15.04.93)
(21) International Application Number: PCT/US92/08477 (22) International Filing Date: 9 October 1992 (09.10.92) (30) Priority data: 773,098 10 October 1991 (10.10.91) US (71)(72) Applicant and Inventor: PANG, Peter. K. T. [US/CA]: 52225 Range Road 232, 205 Carriage Lane, Sherwood Park, Alberta T8A 2A6 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): SHAN, Jie [CN/CA]: 10615-83 Avenue, #105, Edmonton, Alberta T6E 2E3 (CA). (74) Agent: MURRAY, Robert, B.; Nikaido, Marmelstein, Murray & Oram, Metropolitan Square, Suite 330, G Street Lobby, 655 15th Street, N.W., Washington, DC 20005-5701 (US).		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, Euro- pean patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT aa ^{25,26,27} AND USE IN OSTEOPOROSIS TREATMENT (57) Abstract Analogues of bovine and human parathyroid hormone, wherein twenty-fifth, twenty-sixth and twenty-seventh positions of the natural hormone, Arg-Lys-Lys- each have been substituted with Ala, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val have been found to retain bone cell effect with minimal effects on blood pressure and smooth muscle, including cardiac muscle. It has further been found that this effect can be obtained by using a synthetic PTH containing only the first 34 amino acids of PTH, with substitution at the twenty-fifth, twenty-sixth and twenty-seventh amino acids as described. These analogues of PTH also are effective in the treatment of osteoporosis and other bone diseases.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCI on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Sri Lanka	SN	Senegal
CM	Cameroon	LU	Luxembourg	SU	Soviet Union
CS	Czechoslovakia	MC	Monaco	TD	Chad
CZ	Czech Republic	MG	Madagascar	TG	Togo
DE	Germany	ML	Mali	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT
aa^{25, 26, 27} AND USE IN OSTEOPOROSIS TREATMENT

FIELD OF THE INVENTION

5 This invention relates to analogues of parathyroid hormone
which, by substitution at the twenty-fifth, twenty-six and
twenty-seventh positions of natural parathyroid hormone, have
been found to affect calcium change in bone cells without
producing the typical effects of parathyroid hormone on
systolic and diastolic blood pressure, the effects on smooth
10 muscle relaxation, vascular smooth muscle calcium change as
well as positive chronotropic and inotropic effects on the
heart.

BACKGROUND OF THE INVENTION

15 Parathyroid hormone (hereinafter, PTH) is produced by the
parathyroid gland and is involved in the control of calcium
levels in blood. It is a hypercalcemic hormone, elevating
blood calcium levels. PTH is a polypeptide and the amino acid
sequences of bovine and human PTH are closely related. Only
the residues at locations one, seven and sixteen differ between
20 the two. Synthetic polypeptides containing the first thirty-
four residues of PTH may be prepared using the method disclosed
by Erickson and Merrifield, The Proteins, Neurath et al., Eds.,
Academic Press, New York, 1976, page 257, preferably as
modified by the method of Hodges et al., Peptide Research, 1,
25 19 (1988).

When serum calcium is reduced to below a "normal" level,
the parathyroid gland releases PTH and resorption of bone
calcium and increased absorption of calcium from the intestine,
as well as renal reabsorption of calcium, occur.

30 The antagonist of PTH is calcitonin, which acts to reduce
the level of circulating calcium. PTH is known to stimulate
osteoclasts and its activity requires the presence of

derivatives of vitamin D₃, especially 1,25-dihydroxycholecalciferol.

5 Intracellular calcium, particularly in the cells of the vascular system, has been shown to affect changes in vascular tension, as can be measured by changes in blood pressure. U.S. Patent Application 603,745 describes one method which has been discovered to regulate calcium uptake in vascular cells.

10 Osteoporosis is a progressive disease which is particularly characteristic of postmenopausal women, and results in the reduction of total bone mass. The sequelae frequently involve fractures of load-bearing bones and the physical degenerations characteristic of immobilizing injuries. Osteoporosis is associated with hyperthyroidism, hyperparathyroidism, Cushing's syndrome and the use of certain
15 steroidal drugs. Remedies historically have involved increase in dietary calcium, estrogen therapy and increased doses of vitamin D.

PTH has been used to treat osteoporosis. However, while the use of PTH is effective in the treatment of osteoporosis by
20 diminishing the loss of bone mass, PTH may exhibit other undesired pharmacological effects, such as hypotension and smooth muscle relaxation (e.g. relaxation of gastrointestinal organs, uterus, tracheal and vas deferens) as well as positive chronotropic and inotropic effects on the heart. The
25 relaxation effects of PTH on smooth muscle as well as positive chronotropic and inotropic effects of PTH are described in Pang et al, Trends in Pharmacological Sciences, Vol. 7, No. 9, pp. 340-341 (September 1986).

U.S. Patent No. 4,771,124 discloses the property of bovine and human PTH analogues wherein Trp²³ is substituted by amino
30 acids phenylalanine, leucine, norleucine, valine, tyrosine, beta-naphtylalanine and alpha-naphtylalanine as a PTH antagonist. While it was suggested that these analogues might be useful in the treatment of osteoporosis, it was based on the
35 analogues antagonistic action to PTH. Furthermore, there was no data to indicate the effectiveness these analogues on bone or other tissue. In addition, analogues with substituted at

Trp²³ with leucine, phenylalanine or tyrosine would produce undesired secondary effects of smooth muscle relaxation, vascular smooth muscle calcium change as well as positive chronotropic and inotropic effects on the heart.

5 Because PTH is a peptide, topical administration would be the preferred method of administration. However, topical application of PTH or the aforementioned analogues which exhibit vasoactivity would likely produce an undesired local vascular reaction. This reaction could be potentially
10 detrimental if, for example, nasal administration is employed.

 It is one object of this invention to ameliorate bone loss while preventing smooth muscle relaxation as well as positive chronotropic and inotropic effects on the heart and without significantly changing blood pressure. It is another object of
15 this invention to identify that portion of PTH which is responsible for calcium regulation and that portion which appears to be primarily related to control of blood pressure and smooth muscle action.

BRIEF SUMMARY OF THE INVENTION

20 Modification of either bovine or human PTH at each of the twenty-fifth, twenty-sixth and twenty-seventh amino acid positions to substitute for -arginine-lysine-lysine- either alanine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine,
25 methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine produces substantially no change in systolic and diastolic blood pressure, substantially no change in muscle tension and substantially no change in the rate of contraction and the force of contraction of the heart
30 as compared to native PTH. It also has been observed that the PTH analogue containing only the first thirty-four amino acids, with substitution at the twenty-fifth, twenty-sixth and twenty-seventh positions, is equally effective in the "osteo effect" without changing blood pressure or causing muscle relaxation or
35 positive chronotropic and inotropic effects on the heart.

The analogues of the present invention should be effective in ameliorating bone loss while preventing smooth muscle relaxation as well as positive chronotropic and inotropic effects on the heart and without significantly changing blood pressure.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1a shows the structure of natural bovine PTH (SEQ ID NO:1).

Fig. 1b shows the structure of natural human PTH (SEQ ID NO:2).

Fig. 2 shows the structure of bPTH (1-34) with each of positions 25, 26 and 27 substituted with Xaa (SEQ ID NO:3).

Fig. 3 shows the structure of bPTH (1-34) with each of positions 25, 26 and 27 substituted with Ala (SEQ ID NO:4).

Fig. 4 shows the structure of hPTH (1-34) with each of positions 25, 26 and 27 substituted Xaa (SEQ ID NO:5).

Fig. 5 shows the structure of hPTH (1-34) with each of positions 25, 26 and 27 substituted Ala (SEQ ID NO:6).

Fig. 6 shows the structure of bPTH with each of positions 25, 26 and 27 substituted with Xaa (SEQ ID NO:7).

Fig. 7 shows the structure of bPTH with each of positions 25, 26 and 27 substituted with Ala (SEQ ID NO:8).

Fig. 8 shows the structure of hPTH with each of positions 25, 26 and 27 substituted with Xaa (SEQ ID NO:9).

Fig. 9 shows the structure of hPTH with each of positions 25, 26 and 27 substituted with Ala (SEQ ID NO:10).

Fig. 10 shows the effect of bPTH-(1-34) and its analogues on diastolic blood pressure of anesthetized Sprague-Dawley rats.

Fig. 11 shows the effect of bPTH-(1-34) and its analogues on systolic blood pressure of anesthetized Sprague-Dawley rats.

Fig. 12 shows the vasorelaxing effect of bPTH-(1-34) and its analogues on rat tail artery helical strip in vitro.

Fig. 13 shows the depolarizing concentrations of KCl which increased calcium ion levels in cultured osteoblasts. Drug 788 is an anti-osteoporotic agent which inhibits the KCl effect.

Figs. 14 a-d show the depolarizing concentrations of KCl which increased calcium levels in cultured osteoblasts. Addition of bPTH-(1-34) inhibits the KCl effect.

Fig. 15 shows the effect of Cs88 [bPTH-(1-34)] on the mean arterial blood pressure of anesthetized Sprague-Dawley rats.

Fig. 16 shows the dose-response relationship between Cs88 [bPTH-(1-34)] and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.

Fig. 17 shows the effect of Cs88 on $[Ca^{2+}]_i$ in cultured UMR osteoblast cells.

Fig. 18 shows the effect of Cs88 on $[Ca^{2+}]_i$ in cultured UMR cells.

Fig. 19 shows a comparison of the effect of Cs221 and Cs99 and bPTH on the mean arterial blood pressure of anesthetized Sprague-Dawley rats.

Fig. 20 shows the relation between the relaxation curves of Sprague-Dawley rat tail artery helical strips, precontracted with AVP when treated with Cs100, Cs99, Cs88, Cs117 and Cs221.

Fig. 21 shows a comparison between the effect of Cs221 and hPTH on the intracellular calcium uptake in the presence of KCl in UMR cells in culture.

Fig. 22 shows the effect of Cs221 on the intracellular calcium uptake in the presence of KCl in UMR cells in culture.

Fig. 23 shows the effect of Cs1001 on the intracellular calcium uptake in the presence of KCl in UMR cells in culture.

Fig. 24 shows the effect of Cs221 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.

Fig. 25 shows the effect of Cs2001 and Cs1001 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.

DETAILED DESCRIPTION OF THE INVENTION

There are at least two known categories of functions for PTH. PTH is involved in calcium balance in the blood stream and controls both the amount of calcium uptake from the

gastrointestinal tract and the deposition and removal of calcium from bone. Calcium also has been found to be effective in the maintenance of blood pressure. Cox, J. Cardiovascular Pharmacology, Vol. 8 (1986), Supp. 8 S48. Control of calcium in the walls of blood vessels is a useful therapeutic regimen for controlling hypertension and calcium channel blockers, which prevent the introduction of calcium into cell walls, is a conventional therapy for hypertension. Needleman et al. in Goodman and Gilman's The Pharmacological Basis of Therapeutics, MacMillan, New York, (1985), page 816 ff.

Administration of therapeutic doses of PTH has been found to be effective for the control of osteoporosis, particularly in individuals who have been subjected to thyroidectomies/parathyroidectomies. Therapeutic dosages of PTH will, in some individuals, result in unacceptable diminution of blood pressure and may result in relaxation of smooth muscles such as gastrointestinal, uterus, tracheal, vas deferens as well as inhibit positive chronotropic and inotropic effects on the heart. To avoid hypotensive effects, smooth muscle relaxation effects and positive chronotropic and inotropic effects on the heart, it was envisaged that the structure of PTH could be modified to decouple the hypotensive, smooth muscle relaxation and positive chronotropic and inotropic function from the bone calcium and bone deposition function. It has now been discovered that a critical site exists at amino acid twenty-five, twenty-six and twenty-seven, which is -Arg-Lys-Lys- in both bovine and human PTH. Substitution at the -Arg-Lys-Lys- site with -Ala-Ala-Ala- diminishes the hypotensive as well as smooth muscle relaxation and positive chronotropic and inotropic effects without denigrating from the osteo effect. These results suggest that substitution at the -Arg-Lys-Lys- site with amino acids other than basic amino acids arginine and lysine would also diminish the hypotensive, smooth muscle relaxation and positive chronotropic and inotropic effects without denigrating from the osteo effect.

The procedure of Erickson and Merrifield, as modified by Lodges et al., as described above, may be used to synthesize

ve
ng
a
on
he
in
er
al
ed
te
ed
ay
as

he
ng
he
is
re
ly
it
as
ac
TH
co

ls
it
l.
ie
or
is
of
ed
.
ch
t.

According to the method, Ca^{2+} which is present in the cell can be quantified by exciting the dye at two different wavelengths, 340 and 380 nm. The emission fluorescence is measured at 510 nm. The calcium concentration is proportional to the ratio of the fluorescent emission when excited at 340 nm to the emission at 380 nm. It is conventional to report the concentration of calcium within the cell in terms of the fluorescence ratio, the 340/380 ratio. This technique is described in Gryniewicz et al., J. Biol. Chem., 260, 3440 (1985) and Pang et al., P. N. A. S. (USA), 87, 623 (1990).

Figs. 13, 14 a-d, 17, 18, 21, 22 and 23 illustrate the results of the above-described measurements when inhibitors such as an anti-osteoporotic agent (788) or bPTH-(1-34) or Cs114 were used in the presence of KCl.

As can be readily seen from the figures, the PTH analogues, whether full length or 1-34, which contain anomalous amino acids at positions twenty-five, twenty-six and twenty-seven (most particularly those which contain Ala^{25} - Ala^{26} - Ala^{27}), do not effect a hypotensive and smooth muscle relaxation response, including positive chronotropic effects, but do inhibit calcium uptake as stimulated by KCl in osteoblasts, which indicates that these compounds would have the same effect on bone cells as PTH and would be useful in the treatment of osteoporosis in mammals and, particularly, in man, without the aforementioned deleterious side effects in the elderly.

While not being bound by any theory, it is suggested that substitution Arg^{25} - Lys^{26} - Lys^{27} by other amino acids in 1-84 PTH and in the 1-34 analogues removes the vasodepressor, smooth muscle relaxation and positive chronotropic and inotropic effects of either bPTH or hPTH. The effect on KCl induced calcium uptake in osteoblasts, however, is essentially unchanged for 1-84 or 1-34 PTH. In other words, the effect on bone cells is unchanged from PTH.

The physiological significance of an inhibiting effect on the KCl induced calcium uptake in bone cells is not yet understood. One hypothesis is that the analogues interact

fully with bone cell receptor activity. The fact that the same effect is seen for both PTH and the analogues disclosed herein suggests that the site of interaction with the osteoblast cell receptor is unchanged by the substitution.

5 The analogues of the present invention can be used in the treatment of osteoporosis and other bone related diseases and disorders involving bone cell calcium regulation.

10 The analogues of the present invention may be administered to a warm-blooded mammalian in need thereof, particularly a human, by parental, topical, rectal administration or by inhalation. The analogues may be conventionally formulated in a parenteral dosage form compounding about 1 to about 300 mg per unit of dosage with a conventional vehicle, excipient, binder, preservative, stabilizer, color, agent or the like as called for by accepted pharmaceutical practice.

15 For parental administration, a 1 to 10 ml intravenous, intramuscular or subcutaneous injection would be given one to four times daily. The injection would contain an analogue of the present invention in an aqueous isotonic sterile solution or suspension optionally with a preservative such as phenol or 20 a solubilizing agent such as ethylenediaminetetraacetic acid (EDTA). Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are 25 conventionally employed as a solvent or suspending medium. Synthetic monoglycerides, diglycerides, fatty acids (such as oleic acid) find use as fixed oil in the preparation of injectables.

30 For rectal administration, the analogues of the present invention can be prepared in the form of suppositories by mixing with a suitable non-irritating excipient such as cocoa butter or polyethylene glycols.

35 For topical use, the analogues of the present invention can be prepared in the form of ointments, jellies, solutions, suspensions or dermal adhesive patches.

 In a powdered aerosol, analogues of the present invention may be administered by a spinhaler turbo-inhaler device

obtained from Fisons Corporation of Bedford, Massachusetts, at a rate of about 0.1 to 50 mg per capsule, 1 to 8 capsules being administered daily for an average human. In a liquid aerosol, the compounds of the present invention are administered at the rate of about 100 to 1000 micrograms per "puff" or activated release of a standard volume of propellant. The liquid aerosol would be given at the rate of 1 to 8 "puffs" per day with variation in dosages due to the severity of the conditions being treated, the weight of the patient and the particle size distribution of the aerosol. A fluorinated hydrocarbon or isobutane find use as propellants for liquid aerosols.

Daily doses are in the range of about 0.01 to about 200 mg per kg of body weight, depending on the activity of the specific compound, the age, weight, sex and conditions of the subject to be treated, the type and severity of the disease, the frequency and route of administration. As would be well known, the amount of active ingredient that may be combined with the carried materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration.

The following examples demonstrate the utility of applicants' invention. The examples are not limiting, but are illustrative only, and modifications which would be apparent to those skilled in the art are included within the scope of this disclosure.

Example 1

In Vivo Blood Pressure Measurement.

Sprague-Dawley (S-D) rats were anaesthetized with pentobarbital and a cannula was inserted into the carotid artery. The rats were kept sedated during the procedure and were injected with PTH peptides only when the blood pressure of the rats were stable. Peptides were injected through a cannula in the jugular vein, in amounts of 1, 3 and 5 or more $\mu\text{g/kg}$ and the mean systolic and diastolic blood pressure was monitored continuously throughout the procedure. Results are reported with comparison to bPTH-(1-34).

Example 2In Vitro Rat Tail Artery Helical Strip Tension Assay

The assay was performed according to Pang et al., Blood Vessels, 22, 57 (1985). Sprague-Dawley rats were anaesthetized with pentobarbital and the tail artery excised and placed in ice-cold Krebs-Hanseleit solution (KHS) oxygenated with 95% O₂, 5% CO₂. Each artery was cut helically and strips of approximately 1.5 cm were secured in a Sawyer-Bartlestone chamber containing KHS. The force generated by the strips was measured with a Grass FT03 force displacement transducer and recorded on a polygraph. Isolated tail artery helical strips were equilibrated for 1 hour prior to use.

One to two minutes prior to addition of a peptide, the strips were contracted by addition of either arginine vasopressin (AVP), potassium chloride (KCl) or norepinephrine (NE) to the bath. The peptide was then added to the bath and the degree of relaxation measured. Bovine serum albumin was used as a control. Results are reported as percent decrease in tension for each drug and dose used. Drug dose is calculated on the basis of the final concentration in the bath solution.

Example 3In Vitro atrial contractility and contraction rate measurement

The assay was performed according to Tenner et al., Canadian Journal of Physiology and Pharmacology, Vol. 61, No. 10 (1983) pp. 1162-1167. Sprague-Dawley rats weighing between 100 and 250 g were treated with heparin (500 IU, i.p.) 15 minutes prior to decapitation. Thoracotomies were performed and the heart rapidly excised and placed in a cold physiological salt solution (PSS) having the following composition (in millimolar): NaCl, 120; KCl, 5.63; CaCl₂, 2.0; MgCl₂, 2.1; NaHCO₃, 25.0; dextrose, 9.7. The solution was continuously aerated by a gas mixture of 95% O₂-5% CO₂. The right atrium was isolated and suspended in a tissue chamber containing 20 mL of PSS at 37°C, pH 7.4. Atria were allowed to equilibrate for 1 hr under a resting tension of 1 g.

The atrial rate and force were determined from

contractions recorded by a Grass FT.03 force-displacement transducer and a Grass model 79 polygraph. The Basial atrial rate for control atria (as determined by counting the frequency of contractions) was 258 ± 7 bpm ($n=29$). Basal developed force of the spontaneously beating right atria was 0.33 ± 0.06 g ($n=10$). Dose-response curves for the peptides were obtained by cumulative addition of the respective peptides. Drug dose is calculated on the basis of the final concentration in the bath solution.

10 Example 4

Measurement of Intracellular Free Calcium Concentration In Vitro

Intracellular free calcium concentration was measured using the fluorescent dye FURA-2 according to the method of Grynkiewicz et al., J. Biol. Chem., 260, 3440 (1985) and Pang et al., P. N. A. S. (USA), 87, 623 (1990). UMR-106 rat osteosarcoma cells (ATCC CRL-1661) are incubated in 1-10 μ M FURA-2 AM (Sigma Chemical Co., St. Louis), the acetomethoxy ester of FURA-2. Upon hydrolysis within the cell, FURA-2 is released which selectively binds to free Ca^{2+} . Binding to Ca^{2+} shifts the fluorescent spectrum of FURA-2. Quantitation is obtained by exciting the dye at two different wavelengths; preferably 340 and 380 nm and measuring the fluorescent emission at 510 nm. The concentration of calcium is proportional to the ratio of the fluorescence emitted at 340 nm to that at 380 nm.

KCl is used in the medium to stimulate $[\text{Ca}^{2+}]_i$ increase.

After the intracellular $[\text{Ca}^{2+}]_i$ had been measured, the cells were washed with the original medium and the analogues added and the intracellular $[\text{Ca}^{2+}]_i$ measured again. KCl was then added without washing to measure the effect of the analogue on KCl induced $[\text{Ca}^{2+}]_i$ changes. After measurement, the cells were washed with the medium 3-4 times and KCl again added to determine the recovery of the cells after removal of the analogue. Results are shown by actual traces and histograms summarizing the results. As can be seen from Figs.

14 a-d, PTH inhibits intracellular $[Ca^{2+}]_i$ increases as stimulated by KCl and measured by the method. Figs. 18, 21, 22 and 23 illustrate comparable results for the aa^{25,26,27} analogues.

5

The comparability of the analogues and PTH itself is considered to indicate that the analogues would be as useful as PTH for the treatment of osteoporosis.

Table I

<u>Designation</u>	<u>Length</u>	<u>Source</u>	<u>Substitution</u>	<u>Site</u>
Cs88	1-34	bovine	none	
Cs99	1-34	bovine	Ala	25
5 Cs100	1-34	bovine	Ala	26
Cs117	1-34	bovine	Ala	27
Cs 221	1-34	human	Ala	25, 26, 27
Cs1001	1-34	human	none	
Cs2001	1-84	human	none	

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: PANG, Peter K.T.
JIE, Shan
- (ii) TITLE OF INVENTION: PARATHYROID HORMONE ANALOGUES
SUBSTITUTED AT AA ^{25, 26, 27} AND USE IN OSTEOPOROSIS
TREATMENT
- (iii) NUMBER OF SEQUENCES: 10
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Nikaido, Marmelstein, Murray & Oram
 - (B) STREET: 655 Fifteenth Street N.W., Suite 330
 - (C) CITY: Washington D.C.
 - (D) STATE:
 - (E) COUNTRY: United States of America
 - (F) ZIP: 20005-5701
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 773,098
 - (B) FILING DATE: 10-Oct-91
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Murray, Robert B.
 - (B) REGISTRATION NUMBER: 22,890
 - (C) REFERENCE/DOCKET NUMBER: 1610-2002
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (202) 638-5000
 - (B) TELEFAX: (202) 638-4810

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 84 amino acids
 - (B) TYPE: amino acid

17

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His
1 5 10
Leu Ser Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
15 20 25
Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
30 35 40
Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
45 50 55
Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
60 65 70
Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
75 80

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10
Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
15 20 25

18

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala

30

35

40

Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp

45

50

55

Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala

60

65

70

Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln

75

80

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His

1

5

10

Leu Ser Ser Met Glu Arg Val Glu Trp Leu Xaa Xaa Xaa Leu

15

20

25

Gln Asp Val His Asn Phe

30

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His
1 5 10
Leu Ser Ser Met Glu Arg Val Glu Trp Leu Ala Ala Ala Leu
15 20 25
Gln Asp Val His Asn Phe
30

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10
Leu Asn Ser Met Glu Arg Val Glu Trp Leu Xaa Xaa Xaa Leu
15 20 25
Gln Asp Val His Asn Phe
30

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10

20

Leu Asn Ser Met Glu Arg Val Glu Trp Leu Ala Ala Ala Leu
 15 20 25
 Gln Asp Val His Asn Phe
 30

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 84 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His
 1 5 10
 Leu Ser Ser Met Glu Arg Val Glu Trp Leu Xaa Xaa Xaa Leu
 15 20 25
 Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
 30 35 40
 Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
 45 50 55
 Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
 60 65 70
 Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
 75 80

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 84 amino acids
 (B) TYPE: amino acid

21

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His

1 5 10

Leu Ser Ser Met Glu Arg Val Glu Trp Leu Ala Ala Ala Leu

15 20 25

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala

30 35 40

Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp

45 50 55

Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala

60 65 70

Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln

75 80

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 84 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His

1 5 10

Leu Asn Ser Met Glu Arg Val Glu Trp Leu Xaa Xaa Xaa Leu

15 20 25

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
30 35 40
Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
45 50 55
Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
60 65 70
Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
75 80

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10
Leu Asn Ser Met Glu Arg Val Glu Trp Leu Ala Ala Ala Leu
15 20 25
Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
30 35 40
Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
45 50 55
Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
60 65 70
Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
75 80

CLAIMS

1. A bovine parathyroid hormone analogue comprising the structure shown in SEQ ID NO:3, wherein each of Xaa²⁵, Xaa²⁶ and Xaa²⁷ is Alanine (Ala), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic acid (Glu), Glycine (Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenylalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr) or Valine (Val).

2. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:4.

3. A human parathyroid hormone analogue comprising the structure shown in SEQ ID NO:5, wherein each of Xaa²⁵, Xaa²⁶ and Xaa²⁷ is Alanine (Ala), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic acid (Glu), Glycine (Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenylalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr) or Valine (Val).

4. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:6.

5. A bovine parathyroid hormone analogue comprising the structure shown in SEQ ID NO:7, wherein each of Xaa²⁵, Xaa²⁶ and Xaa²⁷ is Alanine (Ala), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic acid (Glu), Glycine (Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenylalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr) or Valine (Val).

6. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:8.

7. A human parathyroid hormone analogue comprising the structure shown in SEQ ID NO:9, wherein each of Xaa²⁵, Xaa²⁶ and Xaa²⁷ is Alanine (Ala), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic acid (Glu), Glycine (Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenylalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr) or Valine (Val).

8. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:10.

9. A pharmaceutical composition comprising a PTH analogue according to any one of claims 1-8 and a pharmaceutically acceptable carrier.

10. A method of treatment of osteoporosis in a patient in need of such treatment without causing substantial induction of hypotension, smooth muscle relaxation and cardiac inotropic and chronotropic action, said method comprising administering an osteoporotic effective amount of a PTH analogue according to any one of claims 1-8.

1 / 19

Fig. 1a

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-
 Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-
 Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-
 Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-
 Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-
 Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-
 Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO₂H

Fig. 1b

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-
 Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-
 Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-
 Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-
 Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-
 Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-
 Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO₂H

Fig. 2

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-
 Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Xaa-
Xaa-Xaa-Leu-Gln-Asp-Val-His-Asn-Phe-CO₂H

Fig. 3

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-
 Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Ala-
Ala-Ala-Leu-Gln-Asp-Val-His-Asn-Phe-CO₂H

Fig. 4

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-
 Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Xaa-
Xaa-Xaa-Leu-Gln-Asp-Val-His-Asn-Phe-CO₂H

Fig. 5

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-
 Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Ala-
Ala-Ala-Leu-Gln-Asp-Val-His-Asn-Phe-CO₂H

Fig. 6

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-
Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Xaa-
Xaa-Xaa-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-
Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-
Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-
Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-
Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO₂H

Fig. 7

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-
Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Ala-
Ala-Ala-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-
Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-
Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-
Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-
Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO₂H

Fig. 8

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-
Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Xaa-
Xaa-Xaa-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-
Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-
Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-
Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-
Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO₂H

Fig. 9

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-
Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Ala-
Ala-Ala-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-
Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-
Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-
Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-
Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO₂H

3/19




FIG. 10

4/19




FIG. 11

5 / 19

Relaxation Effect of PTH Analogues on Rat Tail Artery Elicited by AVP (n=4)

—+— PTH —○— 08117 —▲— 0899 —▽— 08100

Relaxation % Decrease in Tension




Fig. 12

6/19




FIG. 13

7/19




FIG. 14a




FIG. 14c

8/19




FIG. 14b




FIG. 14d

9/19




FIG. 15

10/19




FIG. 16

11/19

EFFECT OF CS88 ON KCL STIMULATED INTRACELLULAR
FREE CALCIUM CONCENTRATION IN CULTURED UMR
OSTEOBLAST CELLS
ACTUAL TRACING OF ONE REPRESENTATIVE EXPERIMENT




FIG.17

12 / 19




FIG. 18




FIG. 19

14/19




FIG. 20

15/19

EFFECTS OF hPTH-(1-34) AND CS221 ON INTRACELLULAR
CALCIUM INCREMENT INDUCED BY KCl 15mM IN UMR CELLS




FIG. 21

16/19





FIG. 22

17/19

EFFECT OF CS 1001 ON INTRACELLULAR
CALCIUM INCREMENT IN UMR (106)



* $P < 0.05$, MEAN VALUE OF FIVE CELLS

FIG. 23




FIG. 24




FIG. 25